期刊文献+

液体活检技术在肺癌诊疗中的研究进展 被引量:3

Research progress of liquid biopsy assay in diagnosis and treatment of lung cancer
暂未订购
导出
摘要 液体活检是一种非侵入性的新型诊断技术,主要检测体液中的游离循环肿瘤细胞、循环肿瘤DNA、外泌体、循环RNA等生物标志物,被广泛用于疾病分子诊断、疗效监测和预后评估。近年来,随着研究的深入及检测技术的发展,液态活检在肺癌诊疗中的应用日益广泛。本文就近年来液体活检技术在肺癌诊疗中的研究进展进行综述。
作者 史琳娜 吕蕊花 贾永军 任革 韩冬 张宏方 贺太平 SHI Lin-na;LYU Rui-hua;JIA Yong-jun
出处 《广西医学》 CAS 2020年第9期1134-1137,1149,共5页 Guangxi Medical Journal
基金 陕西省科技计划(2019JM-551) 陕西中医药大学学科创新团队建设(2019-YS04) 陕西省中医管理局科研课题(JCPT002)。
  • 相关文献

参考文献2

二级参考文献32

  • 1Leighl N B, Rekhtman N, Biermann W A, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase in- hibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline[J]. J Clin Oncol, 2014, 32(32):3673-3679.
  • 2Nakajima T, Yasufuku K, Suzuki M, et al. Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound- guided transbronchial needle aspiration[J]. Chest, 2007, 132(2): 597-602.
  • 3Shih J Y, Gow C H, Yu C J, et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nons- mall cell lung cancer[J]. Int J Cancer, 2006, 118(4):963-969.
  • 4DouiUard J Y, Qstoros G, Cobo M, et al. First-line gefitinib in Cau- casian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study[J]. Br J Cancer, 2014, 110(1):55-62.
  • 5Swaminathan R, Butt A N. Circulating nucleic acids in plasma and serum: recent developments[J]. Ann N Y Acad Sci, 2006, 10751 - 10759.
  • 6Zhao X, Han R B, Zhao J, et al. Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients[J]. Respiration, 2013, 85 (2):119-125.
  • 7Jing C W, Wang Z, Cao H X, et al. High resolution melting analysis for epidermal growth factor receptor mutations in formalin-fixed paraffin-embedded tissue and plasma free DNA from non-small cell lung cancer patients[J]. Asian Pac J Cancer Prev, 2014, 14 (11):6619-6623.
  • 8Brevet M, Johnson M L, Azzoli C G, et al. Detection of EGFR mu- tations in plasma DNA from lung cancer patients by mass spec- trometry genotyping is predictive of tumor EGFR status and re- sponse to EGFR inhibitors[J]. Lung Cancer, 2011, 73(1):96-102.
  • 9Yung T K, Chan K C, Mok T S, et al. Single-molecule detection of epidermal growth factor receptor mutations in plasma by mi- crofluidics digital PCR in non-small cell lung cancer patients[J]. Clin Cancer Res, 2009, 15(6):2076-2084.
  • 10Oxnard G R, Paweletz C P, Kuang Y, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA[J]. Clin Cancer Res, 2014, 20(6):1698-1705.

共引文献229

同被引文献32

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部